SCHEDULE 13D/A: Nantahala Capital Boosts Stake in Aytu BioPharma to 14.4% Through Prefunded Warrant Purchase

Nantahala Capital Management, LLC and its principals have increased their beneficial ownership in Aytu BioPharma, Inc. to 14.4% by acquiring prefunded warrants for 4 million shares in a recent underwritten offering.

Summary

• Nantahala Capital Management, LLC, along with its principals Wilmot B. Harkey and Daniel Mack (collectively, the "Reporting Persons"), filed an Amendment No. 3 to their Schedule 13D regarding Aytu BioPharma, Inc.
• The Reporting Persons now beneficially own an aggregate of 1,086,812 shares of Aytu BioPharma Common Stock, representing 14.4% of the class.
• This increased ownership stems from the purchase of June 2025 Prefunded Warrants by Nantahala Investors in an underwritten offering (the "June 2025 Offering") by Aytu BioPharma on June 6, 2025.
• The Nantahala Investors acquired prefunded warrants exercisable for 4,000,000 shares of Common Stock at a purchase price of $1.4999 per share represented by the warrants.
• The warrants have an exercise price of $0.0001 per share and do not expire, but their exercise is subject to a beneficial ownership limit of 9.99% (which can be increased to 19.99% with 61 days' prior notice).
• The percentage of ownership is based on 7,536,830 shares of Common Stock outstanding immediately after the June 2025 Offering, as communicated by the Issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant and strategic investment by a major capital management firm, suggesting confidence in the issuer. While it's a standard disclosure, the increased stake and the nature of the investment (prefunded warrants) are generally positive signals from the investor's perspective.

Positives

• Nantahala Capital Management, a significant institutional investor, has increased its stake in Aytu BioPharma, indicating a vote of confidence in the company.
• The purchase of prefunded warrants provides a flexible mechanism for Nantahala to increase its ownership over time without immediately exceeding beneficial ownership limits.

Risks

• The exercise of the June 2025 Prefunded Warrants is subject to a beneficial ownership limitation of 9.99% (or up to 19.99% with prior notice), which could restrict the immediate full conversion of the warrants into common stock.

Future Outlook

The June 2025 Prefunded Warrants do not expire except upon exercise in full, allowing the Reporting Persons flexibility in increasing their direct common stock ownership over time, subject to beneficial ownership limitations.

Industry Context

This filing indicates continued investment activity in the biopharmaceutical sector, with institutional investors like Nantahala Capital taking significant stakes in companies like Aytu BioPharma. Such investments can provide crucial capital to the issuer for ongoing operations, research, and development, which is vital in the capital-intensive biopharma industry.

Stakeholder Impact

• Shareholders: Existing shareholders may experience dilution from the issuance of new shares through the underwritten offering and potential future exercise of warrants. However, the investment by Nantahala Capital could be seen as a vote of confidence, potentially stabilizing or increasing share price.
• Aytu BioPharma: The company receives capital from the underwritten offering, which can be used for operations, research, and development, supporting its strategic objectives.

Next Steps

• The Reporting Persons may exercise the June 2025 Prefunded Warrants at any time, subject to beneficial ownership limitations.
• The Issuer's Registration Statement on Form S-1 (filed June 2, 2025) provides further details on the Prefunded Warrants and the offering.

Key Dates

Recommendation

Keywords

AYTU BIOPHARMA, Nantahala Capital Management, Schedule 13D, Prefunded Warrants, Common Stock, Beneficial Ownership, Underwritten Offering, Biopharma, Investment, SEC Filing